Boston Scientific Corporation $BSX Holdings Lowered by Conning Inc.

Conning Inc. trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,130 shares of the medical equipment provider’s stock after selling 254 shares during the quarter. Conning Inc.’s holdings in Boston Scientific were worth $981,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in shares of Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after purchasing an additional 3,932 shares during the last quarter. MRA Advisory Group acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $273,000. Bank of New Hampshire grew its stake in shares of Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd grew its stake in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after purchasing an additional 5,704 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. grew its stake in shares of Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock worth $4,883,000 after purchasing an additional 22,255 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 1st. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Finally, Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $120.71.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $95.41 on Friday. The stock has a market cap of $141.38 billion, a P/E ratio of 56.79, a PEG ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The company has a fifty day moving average price of $101.98 and a 200 day moving average price of $101.87. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.